对于恶性肿瘤患者而言，最可怕的莫过于肿瘤出现转移扩散，因为这意味着肿瘤病变已经发展到晚期，也是肿瘤治疗失败的重要原因之一。9月7日在第七届中国肿瘤学术大会上披露，学术杂志《抗癌研究》（Anticancer Research）刊发了有关中药抑制肿瘤转移的研究报告。
研究证实，我国抗肿瘤创新中药养正消积胶囊可有效抑制肿瘤细胞侵袭转移。研究人员指出，在肿瘤细胞的侵袭转移过程中，磷酸肌醇 3－激酶/蛋白激酶 B(PI3K/AKT) 信号通路的过度激活起到了关键作用，养正消积胶囊可以显著干预 PI3K/AKT 通路，从而对乳腺癌、肠癌、前列腺癌、肺癌、胃癌和骨肉瘤等肿瘤细胞的黏附和迁移起到明显抑制作用，有效控制肿瘤的病变发展。
有关专家介绍，恶性肿瘤细胞非常容易从原发病灶上脱落，每克肿瘤组织每天可向血液中释放300—400万个肿瘤细胞，脱落的肿瘤细胞随血液或淋巴流布全身，一旦条件成熟就会迅速生长，形成转移性病灶。控制肿瘤细胞的侵袭扩散是避免肿瘤恶化、提高肿瘤治疗效果、改善患者生存质量及延长患者寿命的有效措施。
专家认为，这一研究结果对恶性肿瘤的临床治疗具有极高的指导意义，对于尚未出现转移病灶的早中期肿瘤患者，使用养正消积胶囊可以控制肿瘤转移扩散，从而增加手术、介入等治疗手段的成功几率。此外，对于已经发展为全身性病变的晚期肿瘤患者，养正消积胶囊还具有增效减毒作用，可增加化疗疗效，减轻化疗中出现的消化道反应及免疫、造血系统损害，改善患者临床症状，明显提高患者的生存质量，延长患者的生存时间，是辅助治疗恶性肿瘤的一种安全、可靠、疗效满意的治疗方法。
Impact of Yangzheng Xiaoji on the Adhesion and Migration of Human Cancer Cells: the Role of the AKT Signalling Pathway
LIN YE, KE JI, NATASHA FREWER, JIAFU JI and WEN G JIANG
Background: Yangzheng Xiaoji is a traditional Chinese medical formulation that has been shown to have anticancer actions in patients with various solid tumours. The mechanisms of the potential anticancer action of Yangzheng Xiaoji are unknown. In the present study, we investigated the direct effects of Yangzheng Xiaoji on a range of human cancer cell lines and investigated the possible mechanism(s) of its action.
Materials and Methods: Extract of Yangzheng Xiaoji (DME25) was prepared using dimethyl sulfoxide. The influence of DME25 on in vitro growth, adhesion and migration was examined using in vitro function assays. The effects on signalling protein kinases were assessed using western blotting.
Results: DME25 suppressed adhesion and migration of various cancer cell, including those of breast, prostate, lung, osteosarcoma and colorectal cancer. Further investigation showed an involvement of the phosphatidylinositol 3-kinases/protein kinase B (PI3K/AKT) pathway in the inhibitory effect on the adhesion of cancer cells by DME25.
Conclusion: Yangzheng Xiaoji exerts its anticancer effects not only via synergistically working together with chemotherapy, but also by directly inhibiting adhesion and migration of cancer cells. The PI3K/AKT pathway is a potential signalling pathway targeted by Yangzheng Xiaoji.
